Long-Term Outcome of Third Myeloablative Allogeneic Stem Cell Transplantation Using Unrelated Cord Blood: A Case Report.

Authors

Jun Ooi, Seiko Kato, Takaaki Konuma

Published in

Transplantation proceedings. Jul 28, 2026. Epub Jul 28, 2026.

Abstract

Although a second allogeneic stem cell transplantation (SCT2) may cure leukemia relapse after the first allogeneic SCT (SCT1), relapse frequently occurs after SCT2. Recently, several reports on the outcomes of the third allogeneic SCT (SCT3) in patients with relapse after SCT2 have been published. However, no reports have detailed the long-term survival of patients with myeloablative SCT3 using unrelated cord blood (CB). Here, we report the results of our clinical experience in a patient with acute myeloid leukemia (AML) treated with SCT3 using CB after myeloablative conditioning. The patient remains alive and disease-free for 16.8 years after SCT3. To our knowledge, this patient is the longest survivor of AML after SCT3.

PMID:
42521600
Bibliographic data and abstract were imported from PubMed on 29 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.